“Neutralizing Interleukin-13 Increases Skin Microbial Diversity: Results from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Tralokinumab in Adult Patients With Atopic Dermatitis”. 2021. SKIN The Journal of Cutaneous Medicine 5 (6): s56. https://doi.org/10.25251/skin.5.supp.56.